Development of a bayesian forecasting method for warfarin dose individualisation

Pharmaceutical Research

Volumn 28, Issue 5, 2011, Pages 1100-1111

  Wright, Daniel F B ^a   Duffull, Stephen B ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

anticoagulation; optimal design; population pharmacokinetic pharmacodynamic modelling; therapeutic drug monitoring; warfarin

Indexed keywords

WARFARIN;

ARTICLE; BAYES THEOREM; COMPUTER PROGRAM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; EXTERNAL VALIDITY; FORECASTING; HUMAN; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; SIMULATION; SINGLE DRUG DOSE;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BAYES THEOREM; COMPUTER SIMULATION; DRUG DOSAGE CALCULATIONS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; WARFARIN; YOUNG ADULT;

EID: 79955576111     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0369-x     Document Type: Article

References (54)

1. The International Warfarin Pharmacogenetics Consortium 2009 Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med. 360 8 753 64 10.1056/NEJMoa0809329
2. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group 1994 Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity Lancet 343 8896 499 503
3. The Stroke Prevention in Atrial Fibrillation Investigators 1996 Bleeding during antithrombotic therapy in patients with atrial fibrillation Arch Intern Med. 156 4 409 16 10.1001/archinte.156.4.409 (Pubitemid 26067316)
4. M Jones P McEwan CL Morgan JR Peters J Goodfellow CJ Currie 2005 Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population Heart 91 4 472 7 15772203 10.1136/hrt.2004.042465 1:CAS:528:DC%2BD2MXjtlartrs%3D (Pubitemid 40432773)
5. EM Hylek C Evans-Molina C Shea LE Henault S Regan 2007 Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation 115 21 2689 96 17515465 10.1161/CIRCULATIONAHA.106.653048 1:CAS:528:DC%2BD2sXlsVOns7o%3D (Pubitemid 46842784)
6. N Oake DA Fergusson AJ Forster C van Walraven 2007 Frequency of adverse events in patients with poor anticoagulation: a meta-analysis Can Med Assoc J. 176 11 1589 94 10.1503/cmaj.061523 (Pubitemid 46868607)
7. N Oake A Jennings AJ Forster D Fergusson S Doucette C van Walraven 2008 Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis Can Med Assoc J. 179 3 235 44 10.1503/cmaj.080171
8. ES Tan TJ Bonnett AH Abdelhafiz 2007 Delayed discharges due to initiation of warfarin in atrial fibrillation: a prospective audit Am J Ger Pharmacol. 5 3 232 5 10.1016/j.amjopharm.2007.10.006 1:CAS:528:DC%2BD2sXhtlCqtr7O (Pubitemid 350054287)
9. The Stroke Prevention in Atrial Fibrillation Investigators 1996 Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial Lancet 348 9028 633 8 10.1016/S0140-6736(96)03487-3 (Pubitemid 26293807)
10. C van Walraven A Jennings N Oake D Fergusson AJ Forster 2006 Effect of study setting on anticoagulation control Chest 129 5 1155 66 16685005 10.1378/chest.129.5.1155
11. AJ Rose A Ozonoff DR Berlowitz LE Henault EM Hylek 2009 Warfarin dose management affects INR control J Thromb Haemost. 7 1 94 101 18983486 10.1111/j.1538-7836.2008.03199.x 1:CAS:528:DC%2BD1MXitFCms7g%3D
12. L Kalra G Yu I Perez A Lakhani N Donaldson 2000 Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness BMJ 320 7244 1236 9 10797031 10.1136/bmj.320.7244.1236 1:STN:280:DC%2BD3c3lvFehsw%3D%3D (Pubitemid 30240470)
13. BF Gage C Eby JA Johnson E Deych MJ Rieder PM Ridker, et al. 2008 Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin Clin Pharmacol Ther. 84 3 326 31 18305455 10.1038/clpt.2008.10 1:CAS:528:DC%2BD1cXhtVShtr7F
14. M Wadelius M Pirmohamed 2007 Pharmacogenetics of warfarin: current status and future challenges Pharmacogenom J. 7 2 99 111 10.1038/sj.tpj.6500417 1:CAS:528:DC%2BD2sXjvVaqs7s%3D (Pubitemid 46567142)
15. GA McMillin R Melis A Wilson MB Strong NA Wanner RG Vinik, et al. 2010 Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study Ther Drug Monit. 32 3 338 45 20386359 10.1097/FTD.0b013e3181d925bb 1:CAS:528: DC%2BC3cXmsFSmsrg%3D
16. Y Caraco S Blotnick M Muszkat 2007 CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study Clin Pharmacol Ther. 83 3 460 70 17851566 10.1038/sj.clpt.6100316
17. M Wadelius LY Chen JD Lindh N Eriksson MJR Ghori S Bumpstead, et al. 2009 The largest prospective warfarin-treated cohort supports genetic forecasting Blood 113 4 784 92 18574025 10.1182/blood-2008-04-149070 1:CAS:528: DC%2BD1MXhtlGhsbc%3D
18. EA Sconce TI Khan HA Wynne P Avery L Monkhouse BP King, et al. 2005 The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen Blood 106 7 2329 33 15947090 10.1182/blood-2005-03-1108 1:CAS:528:DC%2BD2MXhtVKqt7%2FL (Pubitemid 41510803)
19. P Lenzini M Wadelius S Kimmel JL Anderson AL Jorgensen M Pirmohamed, et al. 2010 Integration of genetic, clinical, and inr data to refine warfarin dosing Clin Pharmacol Ther. 87 5 572 8 20375999 10.1038/clpt.2010.13 1:CAS:528:DC%2BC3cXkvFCntb4%3D
20. JL Anderson BD Horne SM Stevens AS Grove S Barton ZP Nicholas, et al. 2007 Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation Circulation 116 22 2563 70 17989110 10.1161/CIRCULATIONAHA.107.737312 1:CAS:528:DC%2BD2sXhtlagsb3F (Pubitemid 350179221)
21. LB Sheiner S Beal B Rosenberg VV Marathe 1979 Forecasting individual pharmacokinetics Clin Pharmacol Ther. 26 3 294 305 466923 1:STN:280: DyaE1M3jsFagsw%3D%3D (Pubitemid 10194671)
22. LB Sheiner SL Beal 1982 Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods J Pharm Sci. 71 12 1344 8 7153881 10.1002/jps.2600711209 1:STN:280:DyaL3s7htFCnuw%3D%3D (Pubitemid 13209455)
23. SB Duffull S Chadaud P Nony C Laveille P Girard L Aarons 2000 A pharmacokinetic simulation model for ivabradine in healthy volunteers Eur J Pharm Sci. 10 4 285 94 10838018 10.1016/S0928-0987(00)00086-5 1:CAS:528:DC%2BD3cXjs1CgsrY%3D (Pubitemid 30317464)
24. RA O'Reilly PM Aggeler LS Leong 1963 Studies on the coumadin anticoagulant drugs: the pharmacodynamics of warfarin in man J Clin Invest. 42 1542 51 14074349 10.1172/JCI104839
25. RA O'Reilly PM Aggeler 1968 Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose Circulation 38 1 169 77 11712286
26. M Mohammed Abdul X Jiang K Williams R Day B Roufogalis W Liauw, et al. 2008 Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects Br J Pharmacol. 154 1691 700 18516070 10.1038/bjp.2008.210 1:CAS:528:DC%2BD1cXps1Gru7s%3D
27. XM Jiang EYL Blair AJ McLachlan 2006 Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach J Clin Pharmacol. 46 11 1370 8 17050802 10.1177/0091270006292124 1:CAS:528:DC%2BD28Xht1Wjsb3L (Pubitemid 44564366)
28. AK Hamberg M Wadelius JD Lindh ML Dahl R Padrini P Deloukas, et al. 2010 A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age Clin Pharmacol Ther. 87 6 727 34 20410877 10.1038/clpt.2010.37 1:CAS:528:DC%2BC3cXmt1Ojsbs%3D
29. P Jacqmin E Snoeck E van Schaick R Gieschke P Pillai J Steimer, et al. 2007 Modellling response time profile in the absence of drug concentrations: definition and performance evaluation of the K-PD model J Pharmacokinet Pharmacodyn. 34 1 57 85 17051439 10.1007/s10928-006-9035-z 1:STN:280: DC%2BD2s%2FisFOqsQ%3D%3D (Pubitemid 46122548)
30. SB Duffull S Retout F Mentre 2002 The use of simulated annealing for finding optimal population designs Comput Methods Programs Biomed. 69 1 25 35 12088590 10.1016/S0169-2607(01)00178-X (Pubitemid 34667208)
31. NH Holford 2001 Target concentration intervention: beyond Y2K Br J Clin Pharmacol. 52 Suppl 1 55S 9 11564053 10.1046/j.1365-2125.2001.00971.x
32. LB Sheiner 1969 Computer-aided long-term anticoagulation therapy Comput Biomed Res. 2 6 507 18 5367362 10.1016/0010-4809(69)90030-5 1:STN:280: DyaE3c%2Fpt1SktA%3D%3D
33. R Nagashima RA O'Reilly G Levy 1969 Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin Clin Pharmacol Ther. 10 1 22 35 5765183 1:CAS:528:DyaF1MXls1ahtg%3D%3D
34. TG Theofanous RG Barile 1973 Multiple-dose kinetics of oral anticoagulants: methods of analysis and optimized dosing J Pharm Sci. 62 2 261 6 4686401 10.1002/jps.2600620217 1:CAS:528:DyaE3sXovVGltA%3D%3D
35. H Wiegman AM Vossepoel 1977 A computer program for long term anticoagulation control Comput Programs Biomed. 7 2 71 84 405176 10.1016/0010-468X(77)90014-9 1:STN:280:DyaE2s7osVertA%3D%3D (Pubitemid 8097884)
36. LB Wingard Jr RA O'Reilly G Levy 1978 Pharmacokinetics of warfarin enantiomers: a search for intrasubject correlations Clin Pharmacol Ther. 23 2 212 7 620483 1:CAS:528:DyaE1cXkvF2lsLg%3D (Pubitemid 8301090)
37. JM Svec RW Coleman DR Mungall TM Ludden 1985 Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation Ther Drug Monit. 7 2 174 80 4024210 10.1097/00007691-198506000-00006 1:STN:280:DyaL2M3ntlOnsg%3D%3D (Pubitemid 15091115)
38. B Murray R Coleman D McWaters T Ludden D Mungall 1987 Pharmacodynamics of warfarin at steady state Ther Drug Monit. 9 1 1 5 3576653 10.1097/00007691- 198703000-00001 1:CAS:528:DyaL2sXhvVyksL4%3D (Pubitemid 17028015)
39. WF Powers PH Abbrecht DG Covell 1980 Systems and microcomputer approach to anticoagulant therapy IEEE Trans Biomed Eng. 27 9 520 3 7409826 10.1109/TBME.1980.326667 1:STN:280:DyaL3M%2FgsFOmug%3D%3D (Pubitemid 11216665)
40. B Vadher DLH Patterson M Leaning 1999 Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy Br J Clin Pharmacol. 48 1 63 70 10383562 10.1046/j.1365-2125.1999.00967.x 1:CAS:528:DyaK1MXkvFKgsrw%3D (Pubitemid 29296665)
41. PH Abbrecht TJ O'Leary DM Behrendt 1982 Evaluation of a computer-assisted method for individualized anticoagulation: retrospective and prospective studies with a pharmacodynamic model Clin Pharmacol Ther. 32 1 129 36 7083727 10.1038/clpt.1982.136 1:CAS:528:DyaL38XkvVClsL4%3D (Pubitemid 13097285)
42. E Chan R O'Reilly M Rowland 1984 Stereochemical aspects of warfarin in man: a combined pharmacokinetic-pharmacodynamic model Br J Clin Pharmacol. 19 545P
43. NH Holford 1986 Rational warfarin dosing: a pharmacokinetic- pharmacodynamic analysis Clin Pharmacol Ther. [abstract] 39 199
44. E Yuen I Gueorguieva S Wise D Soon L Aarons 2010 Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin J Pharmacokinet Pharmacodyn. 37 1 3 24 19941044 10.1007/s10928-009-9138-4 1:CAS:528: DC%2BC3cXhtFOjsLs%3D
45. AK Hamberg ML Dahl M Barban MG Scordo M Wadelius V Pengo, et al. 2007 A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy Clin Pharmacol Ther. 81 4 529 38 17301738 10.1038/sj.clpt.6100084 1:CAS:528:DC%2BD2sXkvFymu7s%3D (Pubitemid 46452304)
46. M Pitsiu EM Parker L Aarons M Rowland 2003 A Bayesian method based on clotting factor activity for the prediction of maintenance warfarin dosage regimens Ther Drug Monit. 25 1 36 40 12548142 10.1097/00007691-200302000-00005 1:CAS:528:DC%2BD3sXmtVWgtw%3D%3D (Pubitemid 36139823)
47. C Manotti M Moia G Palareti V Pengo L Ria AG Dettori 2001 Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment) Haematologica. 86 10 1060 70 11602412 1:STN:280:DC%2BD3MrlsFOgsw%3D%3D (Pubitemid 33031872)
48. L Poller CR Shiach PK MacCallum AM Johansen AM Munster A Magalhaes, et al. 1998 Multicentre randomised study of computerised anticoagulant dosage Lancet 352 9139 1505 9 9820298 10.1016/S0140-6736(98)04147-6 1:CAS:528:DyaK1cXnsFeltbk%3D (Pubitemid 28512926)
49. PJ Ryan M Gilbert PE Rose 1989 Computer control of anticoagulant dose for therapeutic management Br Med J. 299 6709 1207 9 10.1136/bmj.299.6709.1207 1:STN:280:DyaK3c%2FovFKqsA%3D%3D (Pubitemid 19281174)
50. GW Roberts T Helboe CBM Nielsen AS Gallus I Jensen DG Cosh, et al. 2003 Assessment of an age-adjusted warfarin initiation protocol Ann Pharmacother. 37 6 799 803 12773064 10.1345/aph.1A372 1:CAS:528:DC%2BD3sXkslemsbc%3D (Pubitemid 36618363)
51. Lee J, Lin T. Warfdocs for web version 1.0 Copyright © 2006 Regents of the University of California; 2006 [cited 2010 July 5 2010]; [website]]. Available from: warfdocs.ucdavis.edu.
52. Hamberg AK, Wadelius M, Pirmohamed M, Jonsson EN. Internal and external evaluation of a pharmacometric model for warfarin using prediction corrected visual predicitive check (PC-VPC). Population Approach Group Europe. Nineteenth meeting June 8-11 2010. http://www.page-meeting.org/pdf-assets/2122-Poster- PAGE2010-published.pdf ; Berlin, Germany2010.
53. M Pitsiu EM Parker L Aarons M Rowland 1993 Population pharmacokinetics and pharmacodynamics of warfarin in healthy-young adults Eur J Pharm Sci. 1 3 151 7 10.1016/0928-0987(93)90005-U 1:CAS:528:DyaK2cXhvValtbs%3D (Pubitemid 24055800)
54. J Horsti H Uppa JA Vilpo 2005 Poor agreement among prothrombin time international normalized ratio methods: comparison of seven commercial reagents Clin Chem. 51 3 553 60 15665046 10.1373/clinchem.2004.043836 1:CAS:528:DC%2BD2MXitVOgtrk%3D (Pubitemid 40300231)